NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/27/2026
Back to search
Official data from USPTO
RISKGUARD HEREDITARY CANCER TEST
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
01/28/2026
Trademark type
Combined
Nice classes
5
Filing date
11/22/2024
Registration date
01/27/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/27/2026
Last transaction
01/28/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
03/06/2024
First use in commerce
03/06/2024
Drawing code
5
Owner type
03
Owner location
Madison, WI
Examiner
STANWOOD, STEPHEN D
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized mark "RISKGUARD HEREDITARY CANCER TEST", stacked.
Holders and representatives
Holders
E. C. (pessoa física)
Representatives
Sana Hakim K&L Gates LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Preparations for detecting genetic predispositions for medical purposeshereditary cancer screening test comprised of molecular diagnostic reagents and assays for use in disease detection by detecting DNAchromosomal changesabnormalities or mutations for detection of genes for hereditary canceridentifying hereditary risk associated with cancer and identifying predisposition to cancer; Reagents for medical use; Medical diagnostic assays for testing of body fluids; Medical diagnostic reagents; Medical diagnostic assays for use in disease detection and screening related to cancer
Publications
History of USPTO decisions and trademark events.
27 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/27/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/06/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/06/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
01/06/2026
IUAF
USE AMENDMENT FILED
12/18/2025
EISU
TEAS STATEMENT OF USE RECEIVED
12/18/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/11/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/16/2025
PUBO
PUBLISHED FOR OPPOSITION
09/16/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/10/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/13/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
08/13/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/13/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
08/13/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/13/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/05/2025
GNRT
NON-FINAL ACTION E-MAILED
08/05/2025
CNRT
NON-FINAL ACTION WRITTEN
08/05/2025
DOCK
ASSIGNED TO EXAMINER
07/30/2025
DPCC
DIVISIONAL PROCESSING COMPLETE
07/30/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/23/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/10/2025
ALIE
ASSIGNED TO LIE
01/31/2025
DRRR
DIVISIONAL REQUEST RECEIVED
01/29/2025
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
01/29/2025
NWAP
NEW APPLICATION ENTERED
11/22/2024
Continuous trademark protection
Get notified about every new filing that threatens RISKGUARD HEREDITARY CANCER TEST or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.